An automated method for supporting busulfan therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 315-320

  Juenke, Jo Etta M ^a   Miller, Kendall A ^b   McMillin, Gwendolyn A ^c   Johnson Davis, Kamisha L ^b,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Automated chemistry analyzer; Busulfan; ELISA; Therapeutic drug monitoring

Indexed keywords

BUSULFAN;

ACCURACY; ANALYZER; AREA UNDER THE CURVE; ARTICLE; CHEMICAL ANALYZER; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERMETHOD COMPARISON; PHOTOMETRY; PRIORITY JOURNAL; REPRODUCIBILITY;

AREA UNDER CURVE; AUTOMATION, LABORATORY; BLOOD CHEMICAL ANALYSIS; BUSULFAN; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STATISTICS AS TOPIC;

EID: 80051793115     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318214cd75     Document Type: Article

References (19)

1. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood. 1994;84:2144-2150. (Pubitemid 24296370)
2. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol. 1993;20: 18-25. (Pubitemid 23239401)
3. Rowland M, Tozer TN. Age and Weight: Clinical Pharmacokinetics: Contents and Applications. Philadelphia, PA: Williams and Wilkins; 1995. pp. 233.
4. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transpl. 1995;16:31-42.
5. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Can Chemother Pharmacol. 1989;25: 55-61. (Pubitemid 20000799)
6. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetics and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol. 1989;36: 525-530. (Pubitemid 19135219)
7. Dix SP,Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transpl. 1996;17:225-230. (Pubitemid 26057312)
8. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Sem Oncol. 1993;20: 18-25. (Pubitemid 23239401)
9. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogenic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transpl. 2000;26:463-470.
10. Courtney JB, Harney R, Li Y, et al. Determination of busulfan in human plasma using an ELISA format. Ther Drug Monit. 2009;31:489-494.
11. Heggie JR, Wu M, Burns RB, et al. Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan. J Chromatogr B Biomed Sci Appl. 1997;692:437-444. (Pubitemid 27217848)
12. Peris JE, Latorre JA, Castel V, et al. Determination of busulfan in human plasma using high-performance liquid chromatography with precolumn derivatization and fluorescent detection. J Chromatogr B Biomed Sci Appl. 1999;730:33-40. (Pubitemid 29290603)
13. Jenke A, Renner U, Schuler US, et al. Improved assay for the determination of busulfan by liquid chromatography using post column photolysis. J Chrom B Anal Technol Biomed Life Sci. 2004;805:147-153. (Pubitemid 38534414)
14. Quernin MH, Poonkuzhali B, Montes C, et al. Quantification of busulfan in plasma by gas chromatography-mass spectrometry following derivatization with tetrafluorothiophenol. J Chromatogr B Biomed Sci Appl. 1998;709:47-56. (Pubitemid 28238417)
15. Lai WK, Pang CP, Law LK, et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998;44: 2506-2510.
16. Abdel-Rehim M, Hassan Z, Blomberg L, et al. On-line derivatization utilizing solid-phase microextraction (SPME) for determination of busulphan in plasma using gas chromatography-mass spectrometry (GC-MS). Ther Drug Monit. 2003;25:400-406. (Pubitemid 36638189)
17. Kellogg MD, Law T, Sakamoto M, et al. Tandem mass spectrometry method for the quantitation of serum busulfan. Ther Drug Monit. 2005; 27:625-629. (Pubitemid 41437641)
18. Rauh M, Stachel D, Kuhlen M, et al. Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children: validation of liquid chromatography tandem mass spectrometry method. Clin Pharmacokinet. 2006;45:305-316. (Pubitemid 43327495)
19. Snyder ML, Ritchie JC. Quantification of busulfan in plasma using liquid chromatography electrospray tandem mass spectrometry (HPLC-ESI- MS/MS). Meth Mol Biol. 2010;603:129-136.